Russia’s COVID-19 vaccine — Sputnik V — has been recommended for emergency use authorisation in India following a meeting of the Subject Expert Committee (SEC).
Key takeaways
If approved by the Drug Controller General of India (DCGI), Sputnik V would be the third vaccine to be made available in India after the Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin.
Sputnik V is developed by Russia’s Gamaleya Research Institute of Epidemiology and Microbiology
It claims to be one of the three vaccines in the world with efficacy of over 90%.
The vaccine supplies for the global market will be produced by the Russian Direct Investment Fund (RDIF) international partners in India, Brazil, China, South Korea and other countries.
